{
    "nct_id": "NCT01023867",
    "title": "Comparative Assessment of Clinical Efficacy of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia",
    "status": "COMPLETED",
    "last_update_time": "2016-01-04",
    "description_brief": "To compare the clinical efficacy of donepezil between patients with Alzheimer's disease and Mixed Dementia.",
    "description_detailed": "The purposes of this study are:\n\n1. to compare the clinical efficacy of donepezil between patients with Alzheimer's disease and Mixed Dementia\n2. to help to clinicians in choosing the best treatment for patients with mixed dementia",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil (acetylcholinesterase inhibitor)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests donepezil, a cholinesterase (acetylcholinesterase) inhibitor developed and used to improve cognition and global function in patients with Alzheimer\u2019s disease and related dementias; its intended effect is symptomatic cognitive improvement rather than targeting amyloid or tau pathology. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Act: Key extracted details \u2014 drug: donepezil (oral or transdermal formulations exist); mechanism: reversible acetylcholinesterase inhibitor that increases acetylcholine and produces symptomatic cognitive benefits; approved/used as symptomatic treatment in Alzheimer disease (mild\u2013moderate and severe) and has shown cognitive benefit in vascular cognitive impairment / vascular dementia (relevant because the trial compares AD vs mixed dementia). Sources: PubMed reviews and trials and regulatory/product histories. \ue200cite\ue202turn0search4\ue202turn0search0\ue202turn1search1\ue202turn1search2\ue201",
        "Reflect: Classification check \u2014 according to the category definitions, donepezil is a small-molecule symptomatic cognitive enhancer (does not directly modify Alzheimer pathology like anti-amyloid or anti-tau biologics). Therefore the correct category is 'cognitive enhancer'. The trial description does not state a placebo or comparator arm explicitly (it compares efficacy between diagnostic groups), so no placebo was listed. Note: donepezil has also been studied in vascular dementia/mixed presentations and shown symptomatic cognitive benefits, which supports using the cognitive-enhancer category for a study comparing AD and mixed dementia. \ue200cite\ue202turn0search7\ue202turn1search8\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests donepezil, a reversible acetylcholinesterase (AChE) inhibitor developed to increase acetylcholine and produce symptomatic cognitive improvement (a symptomatic cognitive enhancer rather than an anti-amyloid or anti-tau disease-modifying agent). This mechanism is focused on the cholinergic neurotransmitter system, which maps to CADRO category D: Neurotransmitter Receptors. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "Act: Extracted details \u2014 drug: donepezil; mechanism: reversible, selective acetylcholinesterase inhibitor that increases synaptic acetylcholine to improve cognition and global function; clinical context: used for symptomatic treatment in Alzheimer disease and has shown cognitive benefit in vascular/mixed dementia trials. Based on these details the most specific CADRO match is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search2\ue202turn1search1\ue202turn1search2\ue201",
        "Reflect: Confirming the classification \u2014 donepezil acts on the cholinergic neurotransmitter system (not directly on amyloid, tau, ApoE, inflammation, proteostasis, vasculature remodeling, or neurogenesis). The trial compares symptomatic efficacy between AD and mixed dementia, consistent with a symptomatic neurotransmitter-targeted intervention, not a multi-target or diagnostic study. Therefore D) Neurotransmitter Receptors is the appropriate CADRO category. \ue200cite\ue202turn0search3\ue202turn0search6\ue201",
        "Web search results (key sources cited):",
        "- Donepezil is a specific, reversible acetylcholinesterase inhibitor used for symptomatic treatment of AD; evidence-based reviews summarizing clinical efficacy and mechanism. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "- Pharmacology and clinical trial summaries describing donepezil as a reversible AChE inhibitor with symptomatic cognitive benefits. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "- Randomized, placebo-controlled trials and Cochrane/systematic review evidence showing cognitive benefit of donepezil in vascular dementia / vascular cognitive impairment (relevant to mixed dementia comparisons). \ue200cite\ue202turn1search1\ue202turn1search2\ue202turn1search8\ue201"
    ]
}